News

Nectar Lifesciences Limited informed the National Stock Exchange of India Limited and BSE Limited that its board of directors approved a change in the company`s corporate office from Plot No. 110, Industrial Area, Phase 1, Chandigarh 160 002 to Godrej Eternia, West Wing (Tower A), Plot No. 70, Industrial Area, Phase -1, Chandigarh, 160 002, effective September 15, 2026.

Net Loss of Nectar Lifescience reported to Rs 67.92 crore in the quarter ended March 2026 as against net loss of Rs 130.09 crore during the previous quarter ended March 2025. There were no Sales reported in the quarter ended March 2026 and during the previous quarter ended March 2025.For the full year,net loss reported to Rs 292.89 crore in the year ended March 2026 as against net loss of Rs 113.68 crore during the previous year ended March 2025. There were no Sales reported in the year ended March 2026 as against Rs 21.32 crore during the previous year ended March 2025.Powered by Capital Market - Live News

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 30 May 2026.

Net profit of Nectar Lifescience rose 82.02% to Rs 14.27 crore in the quarter ended December 2025 as against Rs 7.84 crore during the previous quarter ended December 2024. There were no Sales reported in the quarter ended December 2025 and during the previous quarter ended December 2024.Powered by Capital Market - Live News

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 23 January 2026.Powered by Capital Market - Live News